



# National Institute of Standards & Technology

## Report of Investigation

### Reference Material 8392

#### Human DNA for Whole-Genome Variant Assessment

(Family Trio of Eastern European Ashkenazi Jewish Ancestry)

(HG-002, HG-003, HG-004)

This Reference Material (RM) is intended for validation, optimization, and process evaluation purposes. It consists three whole human genome samples from a son-father-mother family trio of Eastern European Ashkenazi Jewish ancestry from the Personal Genome Project (IDs huAA53E0, hu6E4515, and hu8E87A9), and it can be used to assess performance of variant calling from genome sequencing. A unit of RM 8392 consists of three vials containing human genomic DNA from a specific family member; extracted from three large growths of human lymphoblastoid cell lines from the Coriell Institute for Medical Research (Camden, NJ): GM24385 (son) labeled as HG-002, GM24149 (father) labeled as HG-003, and GM24143 (mother) labeled as HG-004. Each vial contains approximately 10 µg of genomic DNA, and the DNA is in TE buffer (10 mM TRIS, 1 mM EDTA, pH 8.0).

This material is intended for assessing performance of human genome sequencing variant calling by obtaining estimates of true positives, false positives, and false negatives. Sequencing applications could include whole genome sequencing, whole exome sequencing, and more targeted sequencing such as gene panels. This genomic DNA is intended to be analyzed in the same way as any other sample a lab would process and analyze extracted DNA. Because the RM is extracted DNA, it is not useful for assessing pre-analytical steps such as DNA extraction, but it does challenge sequencing library preparation, sequencing machines, and the bioinformatics steps of mapping, alignment, and variant calling. This RM is not intended to assess subsequent bioinformatics steps such as functional or clinical interpretation.

**Information Values:** Information values are provided for single nucleotide variations (SNVs), small insertions and deletions (indels), and homozygous reference genotypes. The v3.3.2 benchmark set covers approximately 87 to 88 % of the GRCh37 assembly and 82 to 85 % of the GRCh38 assembly (excluding gaps in the assemblies), using methods described in reference 1. An information value is considered to be a value that will be of interest and use to the RM user, but insufficient information is available to assess the uncertainty associated with the value. We describe and disseminate our best, most confident, estimate of the genotypes using the data and methods currently available. These data and genomic characterizations will be maintained over time as new data accrue and measurement and informatics methods become available. Sequencing data for HG-002, HG-003, and HG-004 can be found under BioSample SAMN03283347, SAMN03283345, and SAMN03283346, respectively, in the National Center for Biotechnology Information (NCBI) Sequence Read Archive. The information values are given as a variant call file (vcf) that contains the benchmark SNVs and small indels, as well as a tab-delimited “bed” file that describes the benchmark regions in which any additional variants not in the benchmark vcf should be errors. Information values cannot be used to establish metrological traceability. The files referenced in this report are available at the Genome in a Bottle ftp site hosted by the NCBI. The Genome in a Bottle ftp site for the benchmark vcf and benchmark regions is:

<ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio>

**Expiration of Value Assignment:** RM 8392 is valid, until **23 December 2024**, provided the RM is handled and stored in accordance with instructions given in this report (see “Instructions for Storage and Use”). This material and associated information values are nullified if the RM is damaged, contaminated, or otherwise modified.

Overall direction and coordination of the analyses was performed by J. Zook and M. Salit of the NIST Biosystems and Biomaterials Division.

Sheng Lin-Gibson, Chief  
Biosystems and Biomaterials Division

Gaithersburg, MD 20899  
Report Issue Date: 01 October 2019  
*Report Revision History on Last Page*

Steven J. Choquette, Director  
Office of Reference Materials

**Maintenance of RM:** This report will be updated periodically to reflect important new releases as the benchmark set is updated. NIST will monitor this RM over the period of its validity. If substantive technical changes occur that affect the value assignment before the expiration of this report, NIST will notify the purchaser. Registration (see attached sheet or register online) will facilitate notification.

Statistical consultation for this RM was provided by D. Samarov of the NIST Statistical Engineering Division.

Technical measurements were conducted by L. Harris, J. McDaniel, and D. Catoe of the NIST Biosystems and Biomaterials Division. Analyses were conducted by J. Zook, N. Olson, J. Wagner, D. Samarov, and J. McDaniel.

Support aspects involved in the issuance of this RM were coordinated through the NIST Office of Reference Materials.

## NOTICE AND WARNINGS TO USERS

RM 8392 is from three human lymphoblastoid cell lines and is intended for research use. Since there is no consensus on the infections status of extracted DNA, handle RM 8392 components as Biosafety Level 1 material potentially capable of transmitting infectious disease, as recommended by the Centers for Disease Control and Prevention (CDC) Office of Safety, Health, and Environment and the National Institutes of Health (NIH) [2].

## INSTRUCTIONS FOR STORAGE AND USE

**Storage:** RM 8392 is stored at  $-20^{\circ}\text{C}$  at NIST but will be shipped with freezer packs and may not arrive frozen. Upon receipt, RM 8392 should be kept in the dark at  $-20^{\circ}\text{C}$  for long-term storage, or in the dark at  $4^{\circ}\text{C}$  for short-term storage (if use is imminent).

**Use:** It is recommended that after comparing a vcf to the benchmark vcf, only the variants inside the benchmark regions be considered as true positives, false positives, and false negatives. In addition, to understand the causes of false positives and false negatives, including the potential for errors in the benchmark set, it is strongly recommended that the user manually inspect aligned reads around a subset of putative false positive and false negatives using a genome browser. To develop standardized definitions for performance metrics and tools to compare variant calls with different representations, the Global Alliance for Genomics and Health Benchmarking Team published best practices for benchmarking germline small-variant calls in human genomes, which we strongly recommend following [3].

As sequencing technologies and analysis methods improve, these benchmark calls and regions will be updated with refined versions of the files in a different directory, and this Report of Investigation will be updated periodically to reflect important new releases. The current release contains small variant benchmark sets with respect to the GRCh37 and GRCh38 reference assemblies from the Genome Reference Consortium. Datasets from a variety of technologies for this genome are described in reference 4.

## SOURCE PREPARATION<sup>(1)</sup>

The DNA for the son in NIST RM 8392 is from the same growth as the DNA in RM 8391 *Human DNA for Whole-Genome Variant Assessment (Son of Eastern European Ashkenazi Jewish Ancestry)*, which contains only the son. Coriell Institute For Medical Research grew a large batch of their cell lines GM24385, GM24149, and GM24143 to produce approximately 107 mg, 35 mg, and 30 mg of total extracted DNA, divided equally into 10 728, 3475, and 3037 vials for the son, father, and mother, respectively. To produce this large quantity of DNA, Coriell started with five aliquots of cells from their stock. These aliquots were pooled, cultured, and split into 50 aliquots. One of these aliquots was taken for quality control, and ten of the aliquots were pooled, split into 21 flasks, grown, and combined. A small amount of these cells was saved for potential future sequencing. The combined 21 growths were mixed and the pool was split into 5 roller bottles, which were again grown and combined. A small amount of these cells was also saved for potential future sequencing. Finally, this large pool was mixed and split into 25 roller bottles, which were grown and combined. A small amount of these cells was also saved for potential future sequencing. This final pool of cells was split into 3 pools for DNA extraction, and the extracted DNA was re-pooled and gently mixed at  $4^{\circ}\text{C}$  for  $>48$  hours before automated aliquoting into vials of 10  $\mu\text{g}$  of DNA.

*Note:* This RM is isolated DNA rather than live cells because cells are less stable and can mutate with each cell division, so that the sequence may not be stable over time for live cells. Extracting DNA from a large batch of cells helps ensure that all vials contain essentially the same sequences of DNA. DNA is currently available from this same

---

<sup>(1)</sup> Certain commercial equipment, instrumentation, or materials are identified in this report to adequately specify the experimental procedure. Such identification does not imply recommendation or endorsement by NIST, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose.

cell line from Coriell, but it may contain small differences in the DNA due to different mutations occurring in different batches of the cells.

**Stability:** Stability was assessed by measuring the size distribution of DNA with pulsed field gel electrophoresis (PFGE). Using PFGE, no change in the size distribution was detected after storage at 4 °C for eight weeks, but the size distribution decreased significantly when stored at 37 °C for 2 weeks or longer. In addition, for similar human DNA materials, we have found that no change is detected after five freeze-thaw cycles, pipetting vigorously, or vortexing. Because we only measure size distribution, we still recommend storing at –20 °C for long periods of time and limiting freeze-thaw cycles, pipetting, and vortexing, particularly if the measurement method requires long, undamaged DNA fragments.

**Homogeneity:** NIST sequenced multiple vials in an experiment designed to assess homogeneity of the samples. No significant differences were detected in terms of proportion of variant or copy number, except for a few in regions known to be susceptible to systematic errors. These results, along with the mixing of DNA before aliquoting, provide confidence that no large differences in small variants or copy number are likely to exist between different vials.

**Size, Concentration, and Volume:** Nominal fragment size length and amount of DNA are useful for judging whether fragment sizes are appropriate for the application and for sample preparation. The characterization of these properties in this RM was intended to determine if they are fit for this purpose.

The fragment size distribution of DNA is suitable for contemporary short read sequencing methods that use fragments less than 1 kb in length. Long and linked read sequencing may be limited by the size distribution of the molecules. HG-002, HG-003, and HG-004 have a peak in the size distribution longer than 48.5 kb, as referenced by Lambda DNA. These size distributions were measured using PFGE, and biases of this method were not characterized.

The nominal concentration of DNA was measured by fluorescence. The mean measured concentration was approximately 300 ng/μl for HG-002, 230 ng/μl for HG-003, and 240 ng/μl for HG-004. The mean volume, as measured by pipette, was 37 μl for HG-002, 45 μl for HG-003, and 44 μl for HG-004. Biases for these measurements were not characterized. It is expected that the user will characterize these properties using measurement methods appropriate for use in their application.

## REFERENCES

- [1] Zook, J.M.; McDaniel, J.; Olsen, N.D.; Wagner, J.; Parikh, H.; Heaton, H.; Irvine, S.A.; Trigg, L.; Truty, R.; McLean, C.Y.; De La Vega, F.M.; Xiao, C.; Sherry, S.; Salit, M.; *An Open Resource for Accurately Benchmarking Small Variant and Reference Calls*; Nat. Biotech., Vol. 37, pp. 561-566 (2019) available at <https://www.nature.com/articles/s41587-019-0074-6> (accessed Oct 2019).
- [2] CDC/NIH: *Biosafety in Microbiological and Biomedical Laboratories*, 5th ed.; HHS publication No. (CDC) 21-1112; Chosewood, L.C.; Wilson, D.E.; Eds.; US Government Printing Office: Washington, D.C. (2009); available at <https://www.cdc.gov/biosafety/publications/bmbl5/> (accessed Oct 2019).
- [3] Krusche, P.; Trigg, L.; Boutros, P.C.; Mason, C.E.; De La Vega, F.M.; Moore, B.L.; Gonzalez-Porta, M.; Eberle, M.A.; Tezak, Z.; L;babidi, S.; Truty, R.; Asimenos, G.; Funke, B.; Fleharty, M.; Chapman, B.A.; Salit, M.; Zook, J.M.; *Best Practices for Benchmarking Germline Small-variant Calls in Human Genomes*; Nat. Biotechnol. Vol. 37, pp. 555-560 (2019).
- [4] Zook, J.M.; Catoe, D.; McDaniel, J.; Vang, L.; Spies, N.; Sidow, A.; Weng, Z.; Liu, Y.; Mason, C.E.; Alexander, N.; Henaff, E.; McIntyre, A.B.R.; Chandramohan, D.; Chen, F.; Jaeger, E.; Moshrefi, A.; Pham, K.; Stedman, W.; Liang, T.; Saghbini, M.; Dzakula, Z.; Hastie, A.; Cao, H.; Deikus, G.; Schadt, E.; Sebra, R.; Bashir, A.; Truty, R.M.; Chang, C.C.; Gulbahce, N.; Zhao, K.; Ghosh, S.; Hyland, F.; Fu, Y.; Chaisson, M.; Xiao, C.; Trow, J.; Sherry, S.T.; Zaranek, A.W.; Ball, M.; Bobe, J.; Estep, P.; Church, G.M.; Marks, P.; Kyriazopoulou-Panagiotopoulou, S.; Zheng, G.X.Y.; Schnall-Levin, M.; Ordonez, H.S.; Mudivarti, P.A.; Giorda, K.; Sheng, Y.; Rypdal, K.B.; Salit, M.; *Extensive Sequencing of Seven Human Genomes to Characterize Benchmark Reference Materials*; Sci. Data 3, 160025 (2016); available at <https://www.nature.com/articles/sdata201625> (accessed Oct 2019).

<b>Report Revision History:</b> 01 October 2019 (Updated title; updated released benchmark set information; editorial changes); 08 September 2016 (Original certificate date).
--

*Users of this RM should ensure that the Report of Investigation in their possession is current. This can be accomplished by contacting the SRM Program: telephone (301) 975-2200; fax (301) 948-3730; e-mail [srminfo@nist.gov](mailto:srminfo@nist.gov); or via the Internet at <https://www.nist.gov/srm>.*